Slider-1
Slider-2
Slider-3
Slider-4

The philosophy of this division is that clinical research is intimately linked to excellence in clinical care.

Clinical trial delivers innovation in cardiovascular medical and device management through dynamic team of practitioners. With cardiovascular disease dominating the cause of mortality and mobility in this regional and US overall, clinical trials evaluate therapies for heart failure, coronary disease and rhythm disorders. It allows clinicians and patients to access evidence based cardiovascular care and device management.

Principle investigator: Lan Luo, MD FACC

 

Clinical Trials

A study to prevent cardiovascular events with diabetes and moderate hypertriglyceridemia

  • Diabetes type II
  • Triglyceride between 200 – 500 mg/dl

A study to evaluate the effect of SGLT2 agent on reducing cardiovascular death or worsening heart failure in patients with heart failure with preserved ejection fraction

  • Heart failure with ejection fraction greater than 40%

A study to access Chelation therapy to prevent recurrent cardiac events in diabetics with prior myocardial infarctions

  • Diabetes type II
  • History of heart attack

A study to evaluate reduction in inflammation in patients with advanced chronic renal disease utilizing antibody medication IL-6 inhibition

  • Chronic renal failure stage III

A study of management of hyperkalemia in patients receiving RAASi medications for the treatment of heart failure

  • Heart failure with ejection fraction less than 40%
  • History of hyperkalemia while on ACEI/ARB/ARA

A device study for heart failure and arrhythmia management

  • History of heart failure requiring hospitalization

A study to access the effect of “DM agent” on cardiovascular outcomes

  • History of cardiovascular disease
  • HgA1C greater than 7%

A study to diagnosis Amyloid cardiomyopathy

  • Heart failure with ejection fraction greater than 40%

A registry study to evaluate PCSK9 on cardiovascular outcomes

  • History of cardiovascular disease
  • Currently on PCSK9 agent

A study to evaluate the efficacy and safety in adult patients with fasting high triglyceride levels and normal renal function

  • Triglyceride level 500 – 2000mg/dl

A study to evaluate the efficacy and safety in adult patients with fasting high triglyceride levels and chronic kidney disease

  • Triglyceride level 500 – 2000mg/dl

Research Trial Coordinator

Summer Waddle
summer.waddle@morganmmc.com
(352) 362-3881